J Korean Soc Matern Child Health.  2021 Jul;25(3):221-229. 10.21896/jksmch.2021.25.3.221.

Clinical Practice Patterns of Hypertensive Disease in Pregnancy among Korean Obstetricians

• Ahn TG
• Kim YH
• Kim YS
• Shin JE
• Oh YL
• Lee SA
• Lee M
• Lee GSR
• Kim SY
• Kim SM
• Hwang JY

• KMID: 2518926
• DOI: http://doi.org/10.21896/jksmch.2021.25.3.221

Abstract

Purpose
The purpose of this study was to investigate the clinical practice patterns of Korean obstetricians and gynecologists the diagnosis and management of hypertensive disease in pregnant women.
Methods
From April 2015 to October 2015, questionnaire was distributed via email to obstetricians who were members of the Society for Maternal and Fetal Medicine. The survey consisted of 37 questions in 6 categories. Responses to the questions on the management of hypertensive disorders of pregnancy, from diagnosis to treatment, were evaluated.
Results
A total of 93 obstetricians and gynecologists responded to the survey. High blood pressure was allocated the highest priority as an index mainly used when deciding to hospitalize patients with hypertensive disease during pregnancy, followed by pregnancy symptoms, proteinuria, and blood test results. Calcium channel blocker (CCB) for oral administration and hydralazine for injection were preferred as antihypertensive drugs mainly used to control severe hypertension. Regarding the delivery method for hypertensive disease during pregnancy, in cases of preeclampsia, 63% of the respondents chose the delivery method according to the cervical status, and in cases of hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome and eclampsia, which increased in severity, 52% and 31% responded that the delivery method was determined according to the cervical status, respectively. In cases of mild preeclampsia, the 70% of respondents preferred 37–38 weeks of gestation for the delivery time. Regarding the use of aspirin in patient with hypertension during pregnancy, 52% of the respondents occasionally administered aspirin, and in patients with a history of hypertensive disease during pregnancy, only 43% were administered prophylactic aspirin.
Conclusion
Domestic obstetricians regarded blood pressure as the most meaningful factor when treating women with hypertension during pregnancy and considered blood pressure control as important. The preferred antihypertensive agents were oral CCB and hydralazine injections, and the choice of delivery method was determined according to the condition of the cervix and severity of the disease. Even in women with high risk factors for preeclampsia, prophylactic aspirin was administered in as low as 50%, of patients, possibly may due to the absence of domestic guidelines for aspirin use during pregnancy. Korean guidelines for prophylactic aspirin administration during pregnancy is needed based on additional research on the efficacy of aspirin for domestic women in the future.

Keyword

Hypertensive disorder of pregnancy, Questionnaire, Clinical practice pattern, Aspirin

Reference

Abalos E., Cuesta C., Grosso AL., Chou D., Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013. 170:1–7.

Benigni A., Gregorini G., Frusca T., Chiabrando C., Ballerini S., Valcamonico A, et al. Effect of low–dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy–induced hypertension. N Engl J Med. 1989. 321:357–62.

Cahill AG., Macones GA., Odibo AO., Stamilio DM. Magnesium for seizure prophylaxis in patients with mild preeclampsia. Obstet Gynecol. 2007. 110:601–7.

Dekker GA., Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol. 1998. 179:1359–75.

Duley L., Henderson–Smart DJ., Walker GJ., Chou D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev. 2010. 2010:CD000127.

Duley L., Meher S., Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013. 2013:CD001449.

Homer CS., Brown MA., Mangos G., Davis GK. Non–proteinuric pre–eclampsia: a novel risk indicator in women with gestational hypertension. J Hypertens. 2008. 26:295–302.

Kim JI. Management of medical complications in pregnancy. J Korean Med Assoc. 2016. 59:5–7.

Koo YJ., Lee DH. Hypertension in pregnancy. J Korean Med Assoc. 2016. 59:24–30.

Levine RJ., Lam C., Qian C., Yu KF., Maynard SE., Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006. 355:992–1005.

Magee LA. CHIPS Study Group. von Dadelszen P., Singer J., Lee T., Rey E, et al. Control of Hypertension In Pregnancy Study randomised controlled trial–are the results dependent on the choice of labetalol or methyldopa? BJOG. 2016. 123:1135–41.

Mol BWJ., Roberts CT., Thangaratinam S., Magee LA., de Groot CJM., Hofmeyr GJ. Pre–eclampsia. Lancet. 2016. 387:999–1011.

Roberge S., Nicolaides K., Demers S., Hyett J., Chaillet N., Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta–analysis. Am J Obstet Gynecol. 2017. 216:110–120. e6.